a b s t r a c t Despite significant progress in understanding the molecular and genetic aspects of amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease characterized by the progressive loss of motor neurons, the precise and comprehensive pathomechanisms remain largely unknown. In addition to motor neuron involvement, recent studies using cellular and animal models of ALS indicate that there is a complex interplay between motor neurons and neighboring non-neuronal cells, such as astrocytes, in non-cell autonomous neurodegeneration. Astrocytes are key homeostatic cells that play numerous supportive roles in maintaining the brain environment. In neurodegenerative diseases such as ALS, astrocytes change their shape and molecular expression patterns and are referred to as reactive or activated astrocytes. Reactive astrocytes in ALS lose their beneficial functions and gain detrimental roles. In addition, interactions between motor neurons and astrocytes are impaired in ALS. In this review, we summarize growing evidence that astrocytes are critically involved in the survival and demise of motor neurons through several key molecules and cascades in astrocytes in both sporadic and inherited ALS. These observations strongly suggest that astrocytes have multi-dimensional roles in disease and are a viable therapeutic target for ALS.
. Genetics reveal ALS is a multifactorial disease. To date, more than 20 genes have been identified for the causes of familial ALS. In this figure, these genes are classified by several known/putative pathways linked to ALS pathomechanisms. Although proteostasis and aberrant RNA metabolism seem to be the most important pathways, there are diverse pathways shared by the multiple ALS genes, indicating that ALS is a multifactorial disease.
in RNA metabolism and proteostasis, mitochondrial dysfunction, ER stress, axonal dysfunction/cytoskeleton, oxidative stress, and glial-mediated neuroinflammation, which suggests multifactorial pathomechanisms in ALS Ling et al., 2013; Philips and Robberecht, 2011; Taylor et al., 2016) (Fig. 1) .
Astrocytes are a key component in the brain environment. They provide neurotrophic factors, control synaptic functions and formation, regulate the concentration of neurotransmitters at synapses, and are involved in a wide range of homeostatic functions (Burda and Sofroniew, 2014) . In the lesions of neurodegenerative diseases, such as in Alzheimer's disease, Parkinson's disease, Huntington's disease, and ALS, astrocytes change their shape and molecular expression patterns, and are referred to as reactive or activated astrocytes (Heneka et al., 2010; Maragakis and Rothstein, 2006; Sofroniew, 2015) (Fig. 2) . This review summarizes accumulating evidence that astrocytes are not just reacting to damage in degenerating neurons but playing profound roles in the process of neurodegeneration in ALS. We discuss the role of astrocytes in familial and sporadic ALS based on the studies using genetically engineered animal models, inducible pluripotent stem (iPS) cell models, and human samples.
SOD1-ALS
Dominant mutations in the SOD1 gene are the second frequent cause of inherited ALS, comprising 20% of familial ALS cases (Bruijn et al., 2004) , while C9orf72 gene-linked inherited ALS is most frequently found except an Asian population. Rodent models that overexpress the human SOD1 gene carrying ALS-linked mutation are widely used in ALS research (Gurney et al., 1994) . Ubiquitous expression of the mutant human SOD1 gene in mice leads to progressive motor neuron degeneration, which partially recapitulates the pathology seen in ALS patients such as selective motor neuron death and gliosis with abnormal accumulation of misfolded, ubiquitinated proteins. Despite the well-known enzyme that catalyzes the conversion of superoxide to oxygen and hydrogen peroxide, all mutant SOD1 proteins uniformly provoke toxicities unrelated to the enzymatic activities (Bruijn et al., 2004; Valentine et al., 2005) . In the lesion of SOD1-ALS rodent models, SOD1 protein inclusions have been observed in motor neurons and glial cells, including astrocytes.
Non-cell autonomous neurodegeneration in ALS
The selective degeneration of motor neurons in ALS initially led researchers to focus on pathogenic mechanisms in motor neurons, i.e. a cell autonomous mechanism. However, recent studies using rodent models of SOD1-ALS indicate that non-cell autonomous pathomechanisms contribute to neurodegeneration and may also be linked to sporadic ALS (Ilieva et al., 2009) . Initial studies showed that the restricted expression of SOD1 mutations in neurons did not lead to neurodegeneration in mice (Lino et al., 2002; Pramatarova et al., 2001) , although one case produced very late onset moderate neurodegeneration (Jaarsma et al., 2008) . Subsequently, the chimeric mouse study demonstrated that wild-type neurons in chimeric mice consisted of both wild-type and mutant SOD1 expressing cells, acquired an ALS phenotype when surrounded by mutant SOD1-carrying glial cells (Clement et al., 2003) . This was further validated in a study using chimeric mice derived from SOD1 G37R mice, in which the mutant SOD1 gene was ubiquitously expressed, and Olig −/− mice which are unable to generate motor neurons and oligodendrocytes. In SOD1 G37R :Olig −/− chimeric mice, all motor neurons are derived from SOD1 G37R -expressing embryonic cells that express the transgene at the same level as mice with ubiquitous expression of mutant SOD1 G37R . In contrast, the cell types other than motor neurons and oligodendrocytes are a mixture of wild type and SOD1 G37R cells. Despite high levels of mutant SOD1 expression in all motor neurons, SOD1 G37R :Olig −/− chimeric mice escaped from motor neuron degeneration and survived longer than SOD1 G37R mice (Yamanaka et al., 2008a) . Therefore, findings from these rodent models of inherited ALS have established the concept of non-cell autonomous neurodegeneration.
Contribution of astrocytes in the experimental models of ALS
In addition to astrogliosis, the abnormal accumulation of mutant SOD1 protein in astrocytes in the spinal cords of SOD1 G85R mice provided a clue about the role of astrocytes in ALS models (Bruijn et al., 1997) . Initial attempt to generate the transgenic mice expressing mutant SOD1 specifically in astrocytes failed to reproduce neurodegenerative phenotypes despite extensive astrogliosis in the spinal cord, indicating that mutant expression in a single cell type may not be sufficient to drive disease (Gong et al., 2000) . Subsequently, studies using chimeric mice identified interactions between motor neurons and glial cells as one of the key mechanisms driving neurodegeneration (Clement et al., 2003; Yamanaka et al., 2008a) . Therefore, we and others have engineered mouse models of ALS in which the mutant SOD1 transgene can be deleted in a cell typespecific manner using the Cre-loxP system. Ablation of the mutant SOD1 transgene in either astrocytes or microglia using floxed SOD1 G37R (loxSOD1 G37R ) or SOD1 G85R mice with Cre recombinase significantly slowed disease progression and extended survival times in mice (Boillee et al., 2006; Wang et al., 2011a Wang et al., , 2009 Yamanaka et al., 2008b) .
Experiments using a cell transplantation approach revealed a detrimental role for mutant astrocytes. Focal transplantation of wild-type astrocyte precursor cells into the cervical spinal cord slowed disease progression and extended survival time in mutant SOD1 rats (Lepore et al., 2008b) . This indicates that improving the cellular environment surrounding motor neurons by transplanting healthy glial cells is a viable therapy for ALS. In a complementary study, a transplantation of mutant SOD1 G93A expressing astrocyteprecursor cells into the spinal cord led to local motor neuron degeneration and moderate motor dysfunction in wild-type mice (Papadeas et al., 2011) . Taken together, these studies indicate that astrocytes play an active role in motor neuron degeneration and provide the basis for cell replacement therapy using astrocytes to slow disease progression in ALS.
A proliferating astrocytic subpopulation, isolated from SOD1 G93A rats have been identified as aberrant astrocytes. They exhibited neurotoxicity in culture and have unique expression profiles with high levels of S100␤, Connexin-43, GFAP, and some microglial markers (Diaz-Amarilla et al., 2011) . However, another study showed that the selective elimination of proliferating astrocytes from SOD1 G93A /GFAP-TK mice failed to alter disease phenotypes (Lepore et al., 2008a) . Therefore, the relevance of this proliferating astrocytic population in neurodegeneration remains unclear.
The interaction between motor neurons and astrocytes has been extensively examined using in vitro co-culture experiments. Several studies using co-cultures of embryonic stem (ES) cell-or iPS cell-derived motor neurons and mutant SOD1-expressing astrocytes have demonstrated that mutant SOD1 astrocytes release toxic substances and reduce motor neuron survival, providing additional support for the role of astrocytes in non-cell autonomous neurodegeneration in ALS (Di Giorgio et al., 2008 Giorgio et al., , 2007 Marchetto et al., 2008; Nagai et al., 2007) . Although the identity of such astrocyte-derived toxicities remained elusive, co-culture systems are advantageous for performing drug screens.
Mechanism of astrocyte-mediated neurotoxicity
Astrocytes in SOD1-ALS models change their phenotypes. One study revealed that astrocytes were immunopositive for ubiquitinated-SOD1, suggesting that they were defective in proteostasis (Bruijn et al., 1997) . A subsequent study demonstrated that those astrocytes had an atypical shape, were immunopositive for cleaved caspase-3, and were located near damaged motor neurons, concluding that they were degenerating astrocytes (Rossi et al., 2008) . This phenotype is similar to that of aberrant astrocytes isolated from mutant SOD1 transgenic rats, which exhibited neurotoxicity in vitro (Diaz-Amarilla et al., 2011). As discussed earlier, aberrant astrocytes have a high rate of proliferation and co-express astrocytic and microglial markers. The authors also observed abnormal astrocytes in the spinal cord of several lines of SOD1-ALS mice (Komine et al., submitted) . The toxicities associated with astrocytes displaying this molecular signature remain to be elucidated.
Several molecules have been linked to the astrocyte-mediated toxicities in studies using SOD1-ALS models. One important function of astrocytes is controlling and reducing extracellular concentrations of glutamate. Excess glutamate at the synaptic cleft results in excessive firing of neurons, thereby increasing the influx of calcium which can be toxic to neurons. This is discussed in more detail in the section on the homeostatic function of astrocytes. In ALS mice, glutamate is also released by activated microglia through gap junctions (Takeuchi et al., 2011) and Xc transporters (Mesci et al., 2015) . Therefore, glutamate is one of the toxic components linked to neuroinflammation in ALS. Another astrocyte-derived molecule linked to excitotoxicity is d-serine, an endogenous coagonist for NMDA receptors. d-serine, which induces glutamate excitotoxicity in motor neurons, is increased in patients with familial and sporadic ALS (Sasabe et al., 2012) . Intriguingly, a mutation in the gene encoding d-amino acid oxidase, which controls the level of d-serine, has been linked to some familial cases of ALS (Mitchell et al., 2010) .
Mitochondrial dysfunction is known as a key mechanism of motor neuron degeneration in ALS. In addition to motor neurons, abnormalities in the mitochondria of astrocytes cause elevated lev-els of reactive oxygen species (ROS), which have been linked to neurodegeneration in SOD1-ALS mice (Cassina et al., 2008) . Similarly, elevated levels of NADPH oxidase (NOX2), inducible nitric oxide synthase (iNOS), and ROS production, which have been observed in human astrocytes expressing mutant SOD1, provoke non-cell autonomous toxicity in human ES-cell derived motor neurons (Marchetto et al., 2008) . Consistent with these observations, an experimental therapeutic approach of overexpressing Nrf2, a transcription factor that upregulates genes encoding anti-oxidants, specifically in astrocytes confers neuroprotection in SOD1-ALS models (Vargas et al., 2008 (Vargas et al., , 2006 .
Proinflammatory cytokines and inflammatory mediators are also linked to astrocyte-mediated toxicities. Interferon stimulated gene 15, which is induced by type 1 interferons (IFN) in astrocytes, was upregulated in the spinal cord of SOD1-ALS mice and sporadic ALS, and eliminating the IFN-␣ receptor 1 extended survival in SOD1 G93A mice (Wang et al., 2011b) . Additionally, mutant SOD1 expressing astrocytes secrete IFN-␥, which induces degeneration in motor neurons in vitro (Aebischer et al., 2011) . The proinflammatory mediator, prostaglandin D 2 (PGD 2 ), has also been linked to motor neuron death in in vitro experiments using co-culture of EScell derived human motor neurons and mutant SOD1 astrocytes (Di Giorgio et al., 2008) .
Transforming growth factor ␤ (TGF-␤) is a multi-functional cytokine involved in many biological functions, including immune homeostasis, neurotrophic response, and microglial development (Butovsky et al., 2014; Li et al., 2006) . Alterations of TGF-␤ signaling have been implicated in ALS due to gene expression profiles from experiments using co-cultures of motor neurons and astrocytes . More recently, the authors demonstrated that astrocyte-derived TGF-␤1 is a negative regulator of the neuroprotective inflammatory response mediated by microglia and T-lymphocytes in ALS mice (Endo et al., 2015) . In summary, a number of molecules discussed here disrupt the complex interaction between astrocytes and motor neurons during disease progression in ALS.
Loss of homeostatic function of astrocytes in ALS
Astrocytes have homeostatic and supportive functions in the brain environment. One of important functions of astrocytes is controlling and reducing the extracellular concentrations of glutamate at the synapse predominantly through the glutamate transporter EAAT2. Evidence suggests that defects in glutamate uptake by astrocytes are due to the loss of the EAAT2 transporter in sporadic and familial ALS cases and in SOD1 mice Bruijn et al., 1997; Guo et al., 2003; Howland et al., 2002; Pardo et al., 2006; Rothstein et al., 1992 Rothstein et al., , 1995 . Riluzole, which reduces the release of glutamate from nerve terminals, is the first approved drug for ALS, consistent with the idea that excitotoxicity contributes to the pathomechanism of ALS. The other study has also linked astrocytes to glutamatemediated neurotoxicity in ALS. Mutant SOD1 expressing astrocytes lose the ability to control expression of the GluR2 subunit of AMPAtype glutamate receptors in motor neurons, leading to an elevated influx of calcium and the demise of motor neurons (Van Damme et al., 2007) .
Another homeostatic function of astrocytes is to support the survival and maintenance of motor neurons by secreting neurotrophic factors, including glial-derived neurotrophic factor (GDNF), brainderived neurotrophic factor, and ciliary neurotrophic factor. Increasing the levels of neurotrophins might confer neuroprotection in ALS. A recent study identified TNF receptor 1 (TNFR1) signaling as a major promoter of GDNF release and synthesis in astrocytes. Ablation of TNFR1 from SOD1-ALS mice accelerated neurodegeneration, indicating that the TNFR1-GDNF pathway may represent a novel therapeutic target for ALS (Brambilla et al., 2016) .
Mitochondrial function in astrocytes is also impaired in ALS. Astrocytes contribute to energy production by providing lactate. Studies have shown that lactate production is reduced in ALS astrocytes and revealed defects in the cellular shuttling of lactate between astrocytes and motor neurons (Cassina et al., 2008; Ferraiuolo et al., 2011; Madji Hounoum et al., 2017) . Moreover, calcium homeostasis in ALS astrocytes is impaired. In cultured astrocytes, the release of excess calcium from endoplasmic reticulum stores and SNARE-dependent exocytosis contribute to astrocyte-mediated toxicity in cases with SOD1 mutation (Kawamata et al., 2014) .
Astrocytes form an intercellular network through gap junction proteins including connexins to maintain homeostatic function in exchanging glucose, lactates, ions, and second messengers. The level of connexin 43, predominant connexin in astrocytes, was upregulated in the spinal cords of SOD1 mice and sporadic ALS patients, as well as human ALS iPS cells-derived astrocytes. Elevated level of connexin 43 in ALS astrocytes provoked toxicities to motor neurons partly through elevated intracellular calcium (Almad et al., 2016) . Changes in the function and molecular expression of astrocytes in ALS are summarized in Fig. 3 .
Astrocytes in TDP-43 linked ALS
TDP-43 was initially identified as a component of ubiquitinated protein inclusions in lesions from sporadic ALS and frontotemporal dementia (FTD) (Arai et al., 2006; Neumann et al., 2006) . Abnormal accumulation of the TDP-43 protein has been detected in lesions of almost all cases of sporadic ALS and many cases of familial ALS. Subsequently, missense mutations were identified in the TDP-43 gene in patients with familial and sporadic ALS and FTD (Lagier-Tourenne et al., 2010; Pesiridis et al., 2009 ). Genetic and pathological evidence indicates that the dysregulation of TDP-43 is central to neurodegeneration in sporadic ALS. TDP-43 possesses multidimensional roles in RNA homeostasis including the regulation of transcription, splicing, transport, and stabilization of mRNAs, micro RNA biogenesis, regulation of non-coding RNAs and cytosolic RNA granules, and spliceosomal integrity (Lee et al., 2012; Ling et al., 2013; Tsuiji et al., 2013) . Moreover, TDP-43 protein has a prion-like domain at carboxyl terminal which is responsible for its aggregate-prone property, suggesting that proteostasis defects are one of the pathomechanisms in ALS (Gitler and Shorter, 2011; Johnson et al., 2008) .
In addition to its accumulation in motor neurons, TDP-43 has also been identified as a main protein component of glial cytoplasmic inclusions (GCI) in oligodendrocytes in ALS (Neumann et al., 2007; Nishihira et al., 2008; Zhang et al., 2008) . Although TDP-43 deposition has been observed in ALS astrocytes, it is more common in oligodendrocytes. In TDP-43 mouse models, several reports have suggested the involvement of glial cells in neurodegeneration, although there is no consensus on a standard model animal for TDP-43-linked ALS (Da Cruz and Cleveland, 2011) . Involvement of NFB in neuroinflammation in TDP-43-linked ALS was demonstrated in sporadic ALS spinal cord and microglia in the mice expressing mutant TDP-43 G348C (Swarup et al., 2011) . Moreover, acute, selective expression of the inducible mutant TDP-43 M337V transgene in astrocytes of rats led to progressive neurodegeneration, indicating that non-cell autonomous pathomechanism might also be involved in TDP-43-linked ALS (Tong et al., 2013) . In contrast, transplanting astrocytic precursor cells derived from mutant TDP-43 A315T mice in the cervical spinal cord of wild-type rats failed to cause pathology in motor neurons (Haidet-Phillips et al., 2013) . The discrepancy between these studies could be partly attributed to the expression Fig. 3 . Multi-dimensional roles of astrocytes in non-cell autonomous neurodegeneration in ALS. In the normal conditions (left), healthy astrocytes support motor neurons by providing neurotrophic factors and metabolic support, and controlling the glutamate concentration at synapses. In ALS (right), astrocytes lose their homeostatic function and fail to support motor neuron health. In addition, they secrete numerous toxic factors that affect motor neurons as illustrated here. Interactions between astrocytes, microglia, and lymphocytes are also implicated in non-cell autonomous neurodegeneration.
level of mutant TDP-43 in astrocytes. Astrocytes also play a role during neurodegeneration in mice with chronic depletion of TDP-43 predominantly in astrocytes . More recently, astrocytes from TDP-43 Q331K transgenic mice showed an impaired antioxidant response partly through the Nrf2 pathway (Moujalled et al., 2017 ).
An in vitro study using astrocytes differentiated from iPS-cell derived from ALS patients demonstrated that mutant TDP-43-expressing astrocytes showed cell-autonomous pathology and die faster than wild-type astrocytes (Serio et al., 2013) . Another in vitro study using conditioned medium obtained from primary astrocytes of mutant TDP-43 transgenic mice exhibited motor neuron death through nitro oxidative stress and sodium channels, indicating noncell autonomous toxicity of astrocytes (Rojas et al., 2014) . Although the molecules in astrocytes that are responsible for neurodegeneration in TDP-43 linked-ALS remain to be identified, glial dysfunction is likely involved in TDP-43 linked ALS.
Astrocytes in sporadic ALS
To understand the role of human astrocytes in sporadic ALS, astrocyte-like cells were initially isolated from fresh postmortem spinal cords of sporadic ALS patients. These patient-derived astrocytes expressed high levels of proinflammatory chemokines, complements, and cytokines (Haidet-Phillips et al., 2011) . They also exhibited non-cell autonomous toxicity to ES-cell derived motor neurons compared with non-disease control astrocytes. In addition, astrocytes derived from sporadic ALS patients triggered necroptosis in motor neurons in a receptor-interacting protein 1 (RIP1) dependent manner (Re et al., 2014) . More recently, by transplanting astrocyte progenitors differentiated from iPS cells of ALS patients to spinal cords of SCID mice, researchers demonstrated that ALS astrocytes cause motor decline and moderate ALS-like motor neuron degeneration in mice (Qian et al., 2017) . The abnormal reduction of HLA-F, an MHC class I molecule in motor neurons is also linked to astrocyte-mediated motor neuron death in sporadic and familial ALS (Song et al., 2016) . Another recent study showed that toxic reactive astrocytes, referred to as A1 astrocytes, were induced by three cytokines released from activated microglia. These astrocytes were also observed in the neurodegenerative disease lesions including sporadic ALS (Liddelow et al., 2017) . Although the molecular basis of astrocyte-mediated toxicities in sporadic ALS remains unclear, accumulating studies indicate that astrocytes are involved in neurodegeneration in sporadic ALS (Fig. 3) .
Astrocytes as therapeutic target for ALS
Throughout this review, we have highlighted ways in which astrocytes are promising therapeutic targets for ALS. The selective ablation of mutant SOD1 from astrocytes slows disease progression in ALS mice (Yamanaka et al., 2008b) . In this study, mutant astrocytes were prone to enhance microglial activation, suggesting a potential role for astrocytes in controlling microglial activation and neuroinflammation. While there are number of methods for controlling neuroinflammation, the authors recently identified TGF-␤1 as a negative regulator of disease progression in ALS through interfering with protective neuroinflammation mediated by microglia and T cells (Endo et al., 2015) . Therefore, astrocytic TGF-␤1 is one of promising targets for future ALS therapy. Alternative approaches for targeting diseased astrocytes include the selective activation of anti-oxidant genes through the Nrf2-ARF pathway (Vargas et al., 2008) , and enhancing the release of neurotrophic factors through the TNF-GDNF pathway (Brambilla et al., 2016) . Moreover, a recent study revealed that abnormal interactions between HLA-F, an MHC class I molecule, in motor neurons and its receptor in the astrocytes contribute to astrocyte-mediated motor neuron death in sporadic and familial ALS (Song et al., 2016) . Finally, targeting gap junction by blocking astrocytic connexin 43 hemichannel is also promising, since a connexin 43 blocker conferred neuroprotection to primary motor neurons co-cultured with ALS astrocytes (Almad et al., 2016) . These molecules may be promising therapeutic targets. In addition to targeted molecular therapies, cell-based therapies, such as transplanting healthy glia-restricted stem cells obviously have great potential.
Conclusion and perspective
The active role of astrocytes in ALS disease mechanisms has been extensively demonstrated and is summarized in Fig. 3 . There are many ongoing or completed clinical trials for ALS that target neuroinflammation. These are summarized in our recent review article (Endo et al., 2016) . Although these trials mainly target microglia/macrophages, some of the molecules may be linked to astrocyte-mediated neuroinflammation. So far, the clinical trials based on the preclinical research using SOD1-ALS mice have been conducted for patients with sporadic ALS; however, almost all of the drugs failed to demonstrate efficacy. The translational failure between rodent models and sporadic ALS patients has been attributed mainly to two reasons: (1) insufficient protocols from rodent studies, including the timing of drug administration and small sample sizes and (2) differences in the disease mechanisms between SOD1-ALS and sporadic ALS (Benatar, 2007) . To fill this translational gap between preclinical and clinical studies, therefore, additional studies are needed to elucidate the common pathomechanisms for astrocyte-mediated neurodegeneration in familial and sporadic ALS. To this end, this review has introduced several candidate molecules that are common to both familial and sporadic ALS. Astrocytes and neuroinflammation have also been the focus of research on other neurodegenerative diseases including Alzheimer's and Parkinson's diseases (Heneka et al., 2015; Hirsch and Hunot, 2009 ). An in-depth understanding of the molecular pathology within astrocytes will accelerate the development of therapies to benefit patients with sporadic and familial ALS.
